Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer

British Journal of Anaesthesia

Volumn 113, Issue SUPPL. 1, 2014, Pages

  Nguyen, J ^a   Luk, K ^a   Vang, D ^a   Soto, W ^a   Vincent, L ^a   Robiner, S ^a   Saavedra, R ^a   Li, Y ^a   Gupta, P ^a,b   Gupta, K ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Minneapolis VA Healthcare System   (United States)

Author keywords

analgesics opioid morphine; angiogenesis lymphangiogenesis; cancer; mast cells; opioid receptor

Indexed keywords

CYTOKINE; MORPHINE SULFATE; MU OPIATE RECEPTOR; PHOSPHATE BUFFERED SALINE; SUBSTANCE P; TUMOR ANTIGEN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUSION GENE; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; LYMPHANGIOGENESIS; MAST CELL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIMIAN VIRUS 40; TRANSGENIC MOUSE; TUMOR GROWTH;

ANALGESICS, OPIOID, MORPHINE; ANGIOGENESIS, LYMPHANGIOGENESIS; CANCER; MAST CELLS; Μ-OPIOID RECEPTOR;

ANALGESICS, OPIOID; ANIMALS; CYTOKINES; DISEASE PROGRESSION; FEMALE; KAPLAN-MEIER ESTIMATE; LYMPHANGIOGENESIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAST CELLS; MICE; MICE, TRANSGENIC; MORPHINE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, OPIOID, MU; SUBSTANCE P;

EID: 84904984408     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeu090     Document Type: Article

References (43)

1. Brogan SE, Winter NB. Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary. Pain Med 2011; 12: 1758-68
2. Greco MT, Corli O, Montanari M, et al. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain 2011; 27: 9-18
3. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angio-genesisbyactivatingproangiogenicandsurvival-promotingsignal-ing and promotes breast tumor growth. Cancer Res 2002; 62: 4491-8
4. Farooqui M, Geng ZH, Stephenson EJ, et al. Naloxone acts as an an-tagonistofestrogenreceptoractivityinMCF-7 cells. Mol Cancer Ther 2006; 5: 611-20
5. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnal-trexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 2006; 72: 3-11
6. Vincent L, Vang D, Nguyen J, et al. Mast cellactivation contributes to sickle cellpathobiologyand paininmice. Blood 2013; 122: 1853-62
7. Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007; 97: 1523-31
8. Singleton PA, Moreno-Vinasco L, Sammani S, et al. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol 2007; 37: 222-31
9. Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 2013; 119: 4103-10
10. Dybendal T, Guttormsen AB, Elsayed S, et al. Screening for mast cell tryptase and serum IgE antibodiesin18patients with anaphylactic shock during general anaesthesia. Acta Anaesthesiol Scand 2003; 47: 1211-8
11. Kolaczkowska E, Seljelid R, Plytycz B. Critical role of mast cells in morphine-mediated impairment of zymosan-induced peritonitis in mice. Inflamm Res 2001; 50: 415-21
12. Veien M, Szlam F, Holden JT, et al. Mechanismsofnonimmunologi-cal histamine and tryptase release from human cutaneous mast cells. Anesthesiology 2000; 92: 1074-81
13. Malfettone A, Silvestris N, Saponaro C, et al. High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med 2013; 17: 1025-37
14. Roy LD, Curry JM, Sahraei M, et al. Arthritis augments breast cancer metastasis: role ofmast cells and SCF/c-Kit signaling. Breast Cancer Res 2013; 15: R32.
15. Munoz M, Covenas R. Involvement of substance Pand the NK-1 receptor in cancer progression. Peptides 2013; 48: 1-9
16. Garcia-Recio S, Fuster G, Fernandez-Nogueira P, et al. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res 2013; 73: 6424-34
17. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994; 91: 11236-40
18. Luk K, Boatman S, Johnson KN, et al. Influence of morphineonperi-cyte- endothelial interaction: implications for antiangiogenic therapy. J Oncol 2012; 2012: 458385.
19. Weber ML, Chen C, Li Y, et al. Morphine stimulates platelet-derived growth factor receptor-b signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo. Br J Anaesth 2013; 111: 1004-12
20. Kohli DR, Li Y, Khasabov SG, et al. Pain-related behaviors and neuro-chemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood 2010; 116: 456-65
21. Arck PC, Handjiski B, Peters EM, et al. Topical minoxidil counteracts stress-induced hair growth inhibition in mice. Exp Dermatol 2003; 12: 580-90
22. Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. Overexpression of the mu-opioid receptorin humannon-small cell lung cancer pro-motesAktandm TOR activation, tumorgrowth, andmetastasis. Anesthesiology 2012; 116: 857-67
23. Mathew B, Lennon FE, Siegler J, et al. The novel role ofthemu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011; 112: 558-67
24. Tegeder I, Grosch S, Schmidtko A, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res 2003; 63: 1846-52
25. Chen C, Farooqui M, Gupta K. Morphine stimulates vascular endo-thelial growth factor-like signaling in mouse retinal endothelial cells. Curr Neurovasc Res 2006; 3: 171-80
26. Kraus J. Regulation of mu-opioid receptorsbycytokines. Front Biosci (Schol Ed) 2009; 1: 164-70
27. Gupta M, Li Y, Gupta K. Opioids as promoters and regulators of angiogenesis. In: Maragoudakis ME, Papadimitriou E, eds. Angio-genesis: Basic Science and Clinical Applications. Trivandrum, Kerala: Transworld Research Network, 2007: 303-17
28. Kajdaniuk D, Marek B, Swietochowska E, Ciesielska-Kopacz N, Buntner B. Is positive correlation between cortisol and met-enkephalin concentration in blood of women with breast cancer a reaction to stress before chemotherapy administration? Patho-physiology 2000; 7: 47-51
29. Boehncke S, Hardt K, Schadendorf D, et al. Endogenous mu-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol 2011; 20: 24-8
30. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20: 4040-9
31. Singleton PA, Mirzapoiazova T, Salgia R, Moss J. Increased mopioid receptor expression in metastatic lung cancer. Br J Anaesth 2014; 113 (S1): i96-i101
32. Fujioka N, Nguyen J, Chen C, et al. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg 2011; 113: 1353-64
33. Madar I, Bencherif B, Lever J, et al. Imaging delta-and mu-opioid receptors by PET in lung carcinoma patients. J Nucl Med 2007; 48: 207-13
34. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010; 140: 460-76
35. Gujam FJ, Going JJ, Edwards J, Mohammed ZM, McMillan DC. The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Crit Rev Oncol Hematol 2014; 89: 231-41
36. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 2001; 22: 146-52
37. Rosa AC, Fantozzi R. The role of histamine inneurogenic inflammation. Br J Pharmacol 2013; 170: 38-45
38. Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, et al. Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int J Immunopathol Pharmacol 2013; 26: 327-35
39. Kandere-Grzybowska K, Gheorghe D, Priller J, et al. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. Brain Res 2003; 980: 213-20
40. Amadesi S, Reni C, Katare R, et al. Role for substance p-based noci-ceptive signaling in progenitor cell activation and angiogenesis during ischemia in mice and in human subjects. Circulation 2012; 125: 1774-86, S1-19
41. Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor2sensitizes transient receptor potential vanilloid1, transientreceptorpotential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 2011; 193: 440-51
42. Lam DK, Schmidt BL. Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway. Pain 2010; 149: 263-72
43. Chang DZ, Ma Y, Ji B, et al. Mast cells in tumor microenvironment promotes theinvivo growthofpancreatic ductal adenocarcinoma. Clin Cancer Res 2011; 17: 7015-23